 Amy Feldman
Concepts (193)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Organ Transplantation | 11 | 2024 | 159 | 4.960 |
Why?
| | Liver Transplantation | 18 | 2023 | 706 | 4.830 |
Why?
| | Biliary Atresia | 10 | 2023 | 183 | 3.050 |
Why?
| | Vaccination | 11 | 2024 | 1205 | 2.840 |
Why?
| | Transplant Recipients | 10 | 2024 | 140 | 2.630 |
Why?
| | Cholestasis | 7 | 2022 | 224 | 2.520 |
Why?
| | Immunization | 5 | 2023 | 401 | 1.810 |
Why?
| | Vaccines | 6 | 2023 | 375 | 1.810 |
Why?
| | Liver Failure, Acute | 2 | 2023 | 58 | 1.360 |
Why?
| | Infant, Newborn, Diseases | 2 | 2021 | 104 | 1.330 |
Why?
| | Pediatrics | 3 | 2021 | 983 | 1.140 |
Why?
| | Communicable Diseases | 2 | 2019 | 129 | 1.080 |
Why?
| | Immunocompromised Host | 4 | 2020 | 195 | 0.990 |
Why?
| | Child | 29 | 2024 | 18352 | 0.980 |
Why?
| | Liver Diseases | 3 | 2022 | 254 | 0.930 |
Why?
| | Vaccines, Attenuated | 2 | 2023 | 112 | 0.900 |
Why?
| | Rubella | 1 | 2023 | 21 | 0.880 |
Why?
| | Mumps | 1 | 2023 | 23 | 0.870 |
Why?
| | Measles | 1 | 2023 | 38 | 0.860 |
Why?
| | Adenoviridae Infections | 1 | 2023 | 15 | 0.840 |
Why?
| | Viral Vaccines | 1 | 2023 | 88 | 0.830 |
Why?
| | Chickenpox | 1 | 2023 | 93 | 0.820 |
Why?
| | Bilirubin | 2 | 2019 | 88 | 0.770 |
Why?
| | Transplantation | 1 | 2021 | 23 | 0.750 |
Why?
| | Hospitalization | 3 | 2019 | 1752 | 0.720 |
Why?
| | Living Donors | 5 | 2023 | 270 | 0.720 |
Why?
| | Waiting Lists | 2 | 2021 | 211 | 0.710 |
Why?
| | Spinal Muscular Atrophies of Childhood | 1 | 2020 | 14 | 0.700 |
Why?
| | Primary Graft Dysfunction | 1 | 2020 | 30 | 0.700 |
Why?
| | Neonatal Screening | 2 | 2019 | 152 | 0.700 |
Why?
| | Immunosuppressive Agents | 4 | 2021 | 647 | 0.690 |
Why?
| | Cholagogues and Choleretics | 1 | 2019 | 8 | 0.660 |
Why?
| | Nutritional Support | 1 | 2019 | 27 | 0.660 |
Why?
| | Oligonucleotides | 1 | 2020 | 137 | 0.650 |
Why?
| | Opportunistic Infections | 1 | 2019 | 43 | 0.650 |
Why?
| | Postoperative Care | 1 | 2020 | 219 | 0.640 |
Why?
| | Postoperative Complications | 3 | 2023 | 2127 | 0.640 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2020 | 123 | 0.640 |
Why?
| | Genetic Therapy | 1 | 2020 | 257 | 0.620 |
Why?
| | Digestive System Surgical Procedures | 1 | 2019 | 90 | 0.620 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 227 | 0.620 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2019 | 92 | 0.610 |
Why?
| | Hospital Costs | 1 | 2019 | 103 | 0.610 |
Why?
| | Registries | 6 | 2023 | 1759 | 0.610 |
Why?
| | Humans | 44 | 2024 | 114756 | 0.610 |
Why?
| | Disease Outbreaks | 1 | 2020 | 309 | 0.560 |
Why?
| | Kidney Transplantation | 1 | 2023 | 541 | 0.560 |
Why?
| | Cross Infection | 1 | 2019 | 197 | 0.560 |
Why?
| | Pyruvic Acid | 1 | 2017 | 42 | 0.550 |
Why?
| | Societies, Medical | 1 | 2020 | 663 | 0.550 |
Why?
| | Immunization Schedule | 1 | 2018 | 184 | 0.540 |
Why?
| | Cytomegalovirus Infections | 2 | 2023 | 182 | 0.540 |
Why?
| | Infant | 10 | 2023 | 7935 | 0.530 |
Why?
| | Mitochondrial Diseases | 1 | 2017 | 77 | 0.530 |
Why?
| | Healthcare Disparities | 1 | 2021 | 479 | 0.530 |
Why?
| | Health Services Accessibility | 2 | 2021 | 763 | 0.530 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2017 | 98 | 0.510 |
Why?
| | Lactic Acid | 1 | 2017 | 275 | 0.490 |
Why?
| | Adaptive Immunity | 2 | 2015 | 156 | 0.490 |
Why?
| | Gastroenterology | 1 | 2016 | 159 | 0.460 |
Why?
| | Rotavirus | 1 | 2013 | 22 | 0.440 |
Why?
| | Rotavirus Infections | 2 | 2013 | 50 | 0.430 |
Why?
| | Infant, Newborn | 5 | 2021 | 5035 | 0.410 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2020 | 1183 | 0.400 |
Why?
| | Reoviridae Infections | 1 | 2012 | 52 | 0.400 |
Why?
| | United States | 7 | 2021 | 12176 | 0.390 |
Why?
| | Child, Preschool | 6 | 2023 | 9079 | 0.380 |
Why?
| | Telemedicine | 1 | 2019 | 663 | 0.380 |
Why?
| | Health Status | 1 | 2016 | 723 | 0.370 |
Why?
| | Anemia, Aplastic | 2 | 2021 | 30 | 0.370 |
Why?
| | Hepatitis | 2 | 2021 | 45 | 0.370 |
Why?
| | Retrospective Studies | 11 | 2023 | 12515 | 0.360 |
Why?
| | Survival Rate | 4 | 2019 | 1642 | 0.350 |
Why?
| | Immunity, Innate | 2 | 2013 | 723 | 0.350 |
Why?
| | Preoperative Period | 2 | 2020 | 103 | 0.340 |
Why?
| | Male | 13 | 2023 | 55579 | 0.330 |
Why?
| | Treatment Outcome | 9 | 2023 | 9089 | 0.320 |
Why?
| | Adolescent | 8 | 2023 | 17808 | 0.310 |
Why?
| | B-Lymphocytes | 1 | 2013 | 769 | 0.310 |
Why?
| | Female | 13 | 2023 | 59507 | 0.310 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1178 | 0.300 |
Why?
| | Graft Rejection | 3 | 2023 | 516 | 0.290 |
Why?
| | Immunization Programs | 2 | 2021 | 205 | 0.290 |
Why?
| | Risk Assessment | 4 | 2022 | 2973 | 0.260 |
Why?
| | Hypertension, Portal | 2 | 2017 | 61 | 0.250 |
Why?
| | Graft Survival | 4 | 2023 | 452 | 0.250 |
Why?
| | Cohort Studies | 3 | 2023 | 4901 | 0.250 |
Why?
| | Quality of Life | 1 | 2016 | 2358 | 0.250 |
Why?
| | Vaccines, Combined | 1 | 2023 | 46 | 0.220 |
Why?
| | Hepatoblastoma | 1 | 2023 | 27 | 0.220 |
Why?
| | Chickenpox Vaccine | 1 | 2023 | 69 | 0.220 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1435 | 0.210 |
Why?
| | Alagille Syndrome | 1 | 2022 | 35 | 0.210 |
Why?
| | Surveys and Questionnaires | 3 | 2021 | 4625 | 0.200 |
Why?
| | Elasticity Imaging Techniques | 1 | 2022 | 40 | 0.200 |
Why?
| | Adenoviridae | 1 | 2023 | 185 | 0.200 |
Why?
| | Sarcoma | 1 | 2023 | 138 | 0.200 |
Why?
| | Incidence | 2 | 2019 | 2312 | 0.200 |
Why?
| | Immunity, Humoral | 2 | 2013 | 112 | 0.190 |
Why?
| | Age Factors | 2 | 2019 | 2890 | 0.190 |
Why?
| | Malnutrition | 1 | 2021 | 63 | 0.180 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2013 | 342 | 0.180 |
Why?
| | Sarcopenia | 1 | 2021 | 63 | 0.180 |
Why?
| | Prednisolone | 1 | 2020 | 75 | 0.170 |
Why?
| | Polymerase Chain Reaction | 1 | 2023 | 994 | 0.170 |
Why?
| | Remission Induction | 1 | 2020 | 233 | 0.170 |
Why?
| | Follow-Up Studies | 2 | 2020 | 4420 | 0.170 |
Why?
| | Liver Neoplasms | 1 | 2023 | 507 | 0.170 |
Why?
| | Prognosis | 2 | 2017 | 3334 | 0.160 |
Why?
| | Vaccination Refusal | 1 | 2020 | 69 | 0.160 |
Why?
| | Postoperative Period | 1 | 2020 | 289 | 0.160 |
Why?
| | Early Diagnosis | 1 | 2019 | 216 | 0.150 |
Why?
| | Morbidity | 1 | 2019 | 277 | 0.150 |
Why?
| | Immunization, Secondary | 1 | 2018 | 82 | 0.150 |
Why?
| | Education, Medical, Graduate | 1 | 2021 | 370 | 0.140 |
Why?
| | Treatment Refusal | 1 | 2018 | 85 | 0.140 |
Why?
| | Tissue and Organ Procurement | 1 | 2020 | 228 | 0.140 |
Why?
| | Transplantation Immunology | 1 | 2017 | 30 | 0.140 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2017 | 24 | 0.140 |
Why?
| | Palivizumab | 1 | 2016 | 13 | 0.140 |
Why?
| | Guideline Adherence | 1 | 2020 | 490 | 0.130 |
Why?
| | Cost-Benefit Analysis | 1 | 2019 | 545 | 0.130 |
Why?
| | Liver Failure | 1 | 2016 | 75 | 0.130 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 386 | 0.130 |
Why?
| | Glucocorticoids | 1 | 2020 | 532 | 0.130 |
Why?
| | End Stage Liver Disease | 1 | 2017 | 63 | 0.130 |
Why?
| | Enterostomy | 1 | 2015 | 8 | 0.130 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2015 | 18 | 0.130 |
Why?
| | Qualitative Research | 1 | 2020 | 935 | 0.130 |
Why?
| | Failure to Thrive | 1 | 2015 | 32 | 0.130 |
Why?
| | Cholangitis | 1 | 2015 | 19 | 0.130 |
Why?
| | Canada | 1 | 2016 | 322 | 0.120 |
Why?
| | Liver | 4 | 2023 | 1631 | 0.120 |
Why?
| | Preoperative Care | 1 | 2017 | 317 | 0.120 |
Why?
| | Attitude to Health | 1 | 2018 | 406 | 0.120 |
Why?
| | Pandemics | 1 | 2022 | 1319 | 0.110 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 977 | 0.110 |
Why?
| | Antigen-Presenting Cells | 1 | 2013 | 153 | 0.110 |
Why?
| | Survivors | 1 | 2016 | 411 | 0.110 |
Why?
| | Th1 Cells | 1 | 2013 | 123 | 0.100 |
Why?
| | Parents | 1 | 2020 | 1190 | 0.100 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 667 | 0.100 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 1796 | 0.100 |
Why?
| | Logistic Models | 1 | 2017 | 1843 | 0.100 |
Why?
| | Sex Factors | 1 | 2017 | 1717 | 0.100 |
Why?
| | Biomarkers | 2 | 2022 | 3416 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2022 | 1727 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1340 | 0.090 |
Why?
| | Immunity, Cellular | 1 | 2012 | 248 | 0.090 |
Why?
| | Antibody Formation | 2 | 2022 | 267 | 0.090 |
Why?
| | Portoenterostomy, Hepatic | 2 | 2023 | 52 | 0.090 |
Why?
| | Flow Cytometry | 1 | 2013 | 1086 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1393 | 0.080 |
Why?
| | Disease Models, Animal | 2 | 2013 | 3542 | 0.070 |
Why?
| | Risk Factors | 1 | 2019 | 8627 | 0.070 |
Why?
| | Hypertension, Pulmonary | 1 | 2015 | 1728 | 0.060 |
Why?
| | Endoglin | 1 | 2022 | 20 | 0.050 |
Why?
| | Matrix Metalloproteinase 7 | 1 | 2022 | 24 | 0.050 |
Why?
| | Cytomegalovirus | 1 | 2023 | 144 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 124 | 0.050 |
Why?
| | Interleukin-8 | 1 | 2022 | 237 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2022 | 208 | 0.050 |
Why?
| | North America | 1 | 2022 | 257 | 0.050 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 228 | 0.050 |
Why?
| | Horses | 1 | 2021 | 96 | 0.040 |
Why?
| | Mice | 2 | 2013 | 14916 | 0.040 |
Why?
| | Enteral Nutrition | 1 | 2021 | 157 | 0.040 |
Why?
| | Tacrolimus | 1 | 2021 | 134 | 0.040 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2022 | 180 | 0.040 |
Why?
| | Animals | 3 | 2021 | 31761 | 0.040 |
Why?
| | Nutritional Status | 1 | 2021 | 286 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2022 | 521 | 0.040 |
Why?
| | Emotional Adjustment | 1 | 2017 | 17 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2023 | 3005 | 0.030 |
Why?
| | Family Relations | 1 | 2017 | 85 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2021 | 2557 | 0.030 |
Why?
| | Health Policy | 1 | 2017 | 334 | 0.030 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 116 | 0.030 |
Why?
| | Bile Ducts | 1 | 2013 | 68 | 0.030 |
Why?
| | Adoptive Transfer | 1 | 2013 | 198 | 0.030 |
Why?
| | Prospective Studies | 1 | 2022 | 6217 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4086 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2013 | 777 | 0.020 |
Why?
| | Virus Diseases | 1 | 2013 | 195 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2013 | 1151 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2539 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2013 | 521 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 1951 | 0.020 |
Why?
| | Autoimmunity | 1 | 2013 | 814 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 6124 | 0.020 |
Why?
| | Disease Progression | 1 | 2013 | 2387 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2099 | 0.010 |
Why?
| | Pregnancy | 1 | 2013 | 5525 | 0.010 |
Why?
|
|
Feldman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|